top of page

Stanley Joel
Mar 3, 20243 min read
Revolutionizing Pharmacovigilance Analytics: Unlocking Insights for Business Innovation and Patient Safety
What lies ahead for reporting and analytics in pharmacovigilance? Will it drive business innovation as patient safety transitions from a...
13,935 views0 comments

Stanley Joel
Feb 12, 20243 min read
Pharmacovigilance Essentials: Key Principles of Safety Database Management
In the realm of pharmaceuticals, ensuring the safety of medicines is paramount. Pharmacovigilance, the science and activities relating to...
7 views0 comments

Stanley Joel
Jan 29, 20245 min read
Accelerating Progress: The Automation Advantage in Literature Review for Pharmacovigilance
Pharmacovigilance, the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or...
9,225 views0 comments

Stanley Joel
Jan 22, 20243 min read
Navigating the Seas of Literature Review and Monitoring in Pharmacovigilance: Challenges, Solutions, and the Crypta Advantage
In the ever-evolving landscape of pharmacovigilance, the importance of a comprehensive literature review and monitoring system cannot be...
13,142 views0 comments
bottom of page